This question set covers the conceptual foundation on which all antianginal pharmacology rests: what myocardial ischemia is, why it happens, how angina is classified, and which hemodynamic levers are available to pharmacological intervention. You will not be asked about specific drug doses or trial data in this set — the goal is to make the framework solid before the drugs are introduced. Some questions are straightforward recall; others ask you to connect a concept to its clinical or pharmacological consequence. Read every rationale, including for questions you answered correctly — the rationale often contains the reasoning that separates a confident answer from a lucky one. Pay particular attention to the vasospastic angina questions and the combination therapy rationale — these carry the most direct prescribing consequences.
1. Of the four major determinants of myocardial oxygen consumption (MVO2) — heart rate, ventricular wall stress, contractility, and myocardial mass — which one is considered the single most important, and why does increasing it simultaneously worsen both the demand side and the supply side of the oxygen balance equation?
A) Ventricular wall stress, because it is determined by both preload and afterload and therefore represents the combined hemodynamic burden on the myocardium
B) Myocardial contractility, because greater force of contraction requires proportionally more ATP hydrolysis and cross-bridge cycling than any other determinant
C) Heart rate, because each additional cycle multiplies total oxygen expenditure and tachycardia disproportionately shortens diastole, simultaneously reducing the time available for coronary perfusion
D) Myocardial mass, because hypertrophied ventricles consume more oxygen at baseline and are more susceptible to subendocardial ischemia under any level of demand
E) Preload, because elevated left ventricular end-diastolic pressure increases wall stress via the Law of Laplace and compresses subendocardial vessels, reducing perfusion
ANSWER: C
Rationale:
This question asked you to identify the primary determinant of MVO2 and explain why it uniquely penalizes both sides of the oxygen balance equation. Heart rate (Option C) holds this position for two compounding reasons: first, each cardiac cycle consumes energy, so doubling heart rate nearly doubles oxygen consumption; second, tachycardia disproportionately shortens diastole — and since the left ventricle is perfused predominantly during diastole, tachycardia simultaneously increases demand and reduces supply. No other determinant carries this dual penalty.
Option A: Option A is incorrect as the primary answer: ventricular wall stress is a major MVO2 determinant and the rationale correctly identifies its determinants, but it does not carry the supply-side penalty that heart rate does, and it is ranked below heart rate in pharmacological importance.
Option B: Option B is incorrect as the primary answer: contractility is a genuine MVO2 determinant because greater force requires more ATP hydrolysis, but its magnitude of effect is ranked below heart rate, and increasing contractility does not directly reduce coronary perfusion time.
Option D: Option D is incorrect as the primary answer: myocardial mass is a determinant of baseline MVO2 and does increase subendocardial vulnerability, but it is not acutely modifiable and is not ranked as the primary pharmacological target.
Option E: Option E is incorrect as the primary answer: elevated LVEDP does compress subendocardial vessels and contributes to wall stress, but preload is not classified as a primary MVO2 determinant in the same tier as heart rate; it is an important therapeutic lever via its effect on wall stress, but the unique dual supply-demand penalty belongs to heart rate alone.
2. A medical student asks why the myocardium is so much more vulnerable to ischemia than skeletal muscle when coronary flow is transiently reduced. The correct explanation centers on a fundamental difference in baseline oxygen extraction. Which of the following accurately describes this difference and its pharmacological consequence?
A) The myocardium extracts approximately 70–75% of delivered oxygen at rest, leaving almost no extraction reserve; when demand rises, it must increase coronary blood flow rather than extract more from existing flow — making any fixed limitation on flow immediately ischemic
B) The myocardium and skeletal muscle extract oxygen at similar rates at rest, but the myocardium is more vulnerable because it cannot shift to anaerobic metabolism during brief ischemic episodes
C) The myocardium extracts approximately 40% of delivered oxygen at rest, comparable to other high-demand organs, but its dense capillary network makes it more sensitive to vasospasm than skeletal muscle
D) Skeletal muscle extracts more oxygen per gram of tissue than the myocardium at rest because of its higher mitochondrial density, but the myocardium compensates by upregulating extraction during stress
E) The myocardium extracts nearly 100% of delivered oxygen at rest, meaning that any reduction in coronary flow immediately exhausts the oxygen supply and triggers cell death within seconds
ANSWER: A
Rationale:
This question asked you to identify the correct baseline oxygen extraction figures and explain why they determine myocardial ischemia vulnerability. Option A is correct: the myocardium extracts approximately 70–75% of delivered oxygen at rest, compared to approximately 25% in skeletal muscle at rest. Because extraction is already near-maximal at baseline, the myocardium has almost no extraction reserve — it cannot respond to increased demand by simply extracting more from existing blood flow. Instead, it is entirely dependent on increasing coronary blood flow. A fixed stenosis that limits this flow increase creates an ischemic threshold at a predictable level of demand, which is the pathophysiological basis of stable angina.
Option B: Option B is incorrect because the extraction rates are not similar at rest; the difference in baseline extraction ratio is the specific explanation for myocardial vulnerability, not an inability to shift metabolism.
Option C: Option C understates the myocardial extraction rate at approximately 40% — this figure is too low and would not correctly explain the near-complete dependence on flow augmentation.
Option D: Option D inverts the relationship: skeletal muscle extraction at rest is substantially lower than myocardial extraction, not higher; and the myocardium does not upregulate extraction during stress in any meaningful way.
Option E: Option E overstates the extraction rate: near-100% extraction would leave no oxygen in coronary venous blood, which does not reflect measured coronary sinus oxygen saturations; the correct figure of approximately 70–75% already explains the vulnerability without requiring this extreme.
3. A cardiology fellow uses the Law of Laplace to explain why left ventricular hypertrophy (LVH) transiently reduces anginal symptoms even though it increases total myocardial oxygen demand. Which of the following correctly states the Law of Laplace as applied to ventricular wall stress and identifies the correct directional effect of each variable?
A) Wall stress = pressure × radius; wall thickness is not incorporated into the cardiac Laplace relationship because myocardial fiber geometry renders it pharmacologically irrelevant
B) Wall stress = pressure × radius × wall thickness; thicker walls generate proportionally greater stress per unit area and therefore worsen ischemia in hypertrophied ventricles
C) Wall stress = pressure / (radius × wall thickness); elevated filling pressure reduces wall stress because it is in the denominator of this formulation
E) Wall stress = (pressure × radius) / (2 × wall thickness); elevated filling pressures increase end-diastolic radius and raise wall stress, while ventricular hypertrophy increases wall thickness and reduces wall stress per unit area — the short-term compensatory benefit of LVH
ANSWER: E
Rationale:
This question asked you to identify the correct formulation of the Law of Laplace for ventricular wall stress and interpret the directional effect of each variable. Option E is correct: Wall Stress = (Pressure × Radius) / (2 × Wall Thickness). Elevated filling pressures (preload) increase end-diastolic radius, raising wall stress and MVO2. Elevated systemic vascular resistance (afterload) increases systolic pressure, also raising wall stress. Ventricular hypertrophy increases wall thickness, which is in the denominator — this reduces wall stress per unit area and is the short-term compensatory benefit of LVH, even though the hypertrophied myocardium has increased total MVO2 due to greater myocardial mass. Option B places wall thickness in the numerator as a multiplier, which inverts its actual role: thicker walls reduce, not increase, stress per unit area — this is why the Laplace relationship explains LVH as a compensatory mechanism. Option C places pressure in the numerator and radius and thickness in the denominator, which incorrectly implies that elevated filling pressure would reduce wall stress; the correct formula places pressure and radius in the numerator, meaning elevated pressure raises wall stress.
Option A: Option A incorrectly omits wall thickness from the formula entirely and misstates that it is pharmacologically irrelevant; wall thickness is the denominator and directly determines how much stress each unit of myocardium must bear.
Option D: Option D inverts the positions of radius and wall thickness relative to the correct formula, implying that larger ventricular radius reduces wall stress — this is the opposite of the correct relationship; dilated ventricles have increased wall stress, not reduced, which is why dilated cardiomyopathy carries a high MVO2 burden.
4. A resident reviewing an exercise stress test report notes that the patient's anginal threshold was reached at a "rate-pressure product" of approximately 26,000 mmHg·beats/min. She asks her attending to explain what this number represents and how it should guide antianginal therapy. Which of the following responses is correct?
A) The rate-pressure product equals heart rate divided by systolic blood pressure and reflects the efficiency of oxygen delivery per cardiac cycle; a lower value indicates greater ischemic risk
B) The rate-pressure product equals heart rate multiplied by systolic blood pressure and serves as a reliable bedside surrogate for MVO2; because a given patient reaches their ischemic threshold at a reproducible rate-pressure product, effective antianginal therapy should reduce the resting rate-pressure product by at least 15–20% from baseline so that ordinary activities no longer approach that threshold
C) The rate-pressure product equals heart rate multiplied by diastolic blood pressure and reflects coronary perfusion pressure; a high value indicates adequate diastolic filling and reduced ischemic risk
D) The rate-pressure product equals mean arterial pressure multiplied by heart rate and is primarily used in critical care settings to titrate inotropic support; it has limited applicability in outpatient angina management
E) The rate-pressure product equals systolic blood pressure multiplied by stroke volume and is a surrogate for cardiac output; antianginal therapy aims to increase it toward normal by reducing afterload
ANSWER: B
Rationale:
This question asked you to correctly define the rate-pressure product (RPP) and apply it to antianginal therapy planning.
Option B: Option B is correct: RPP = HR × systolic BP. It is the most clinically useful bedside surrogate for MVO2 and reliably predicts the anginal threshold in individual patients — the same patient will reach their ischemic threshold at a reproducible RPP under comparable conditions. Effective antianginal therapy shifts this demand curve downward, so that ordinary daily activities no longer reach the ischemic threshold. The therapeutic target is a resting heart rate of 55–60 beats per minute and a resting RPP reduced by at least 15–20% from pre-treatment baseline.
Option A: Option A uses division rather than multiplication, which is arithmetically incorrect; a rate-pressure product calculated by division would not scale with increasing demand and would not correlate with MVO2.
Option C: Option C substitutes diastolic blood pressure for systolic blood pressure and mischaracterizes the RPP as a perfusion pressure surrogate — coronary perfusion pressure is actually approximated by aortic diastolic pressure minus LVEDP, which is a different calculation entirely.
Option D: Option D substitutes mean arterial pressure (MAP) for systolic blood pressure and incorrectly limits the RPP to critical care use; while MAP is used in other hemodynamic calculations, the standard bedside RPP uses systolic blood pressure and is explicitly applicable to outpatient stable angina management.
Option E: Option E substitutes stroke volume for heart rate, which produces a formula for a different hemodynamic variable entirely (approximating a component of cardiac work) rather than the RPP.
5. An echocardiogram performed during exercise stress testing reveals a regional wall motion abnormality before the patient reports any chest discomfort. An attending uses this finding to illustrate the concept of the "ischemic cascade." Which of the following correctly describes the sequence of events in the ischemic cascade from the earliest to the latest manifestation?
This question asked you to identify the correct chronological sequence of the ischemic cascade. Option D is correct: metabolic changes occur first (lactate production begins as oxidative phosphorylation is outstripped, ATP depletion follows), then diastolic dysfunction develops (impaired myocardial relaxation is an early and sensitive marker of ischemia, detectable before any wall motion change), then systolic dysfunction appears as regional wall motion abnormalities (reflecting contractile failure in the ischemic zone), then ECG changes emerge (ST depression or elevation, reflecting transmural electrical heterogeneity), and finally anginal symptoms appear last. The critical clinical implication is that ischemia is already physiologically significant — with measurable metabolic and mechanical consequences — well before the patient reports any symptoms. Symptom-guided therapy alone may therefore substantially underestimate the true burden of ischemia, particularly in patients with diabetic autonomic neuropathy or high pain thresholds. Option C begins correctly with diastolic dysfunction but then misplaces metabolic changes after systolic dysfunction, when in fact metabolic abnormalities (lactate production) are the earliest event in the cascade and precede any mechanical dysfunction.
Option A: Option A is incorrect because it places symptoms first, which is the reverse of the actual sequence; symptoms are the final manifestation of ischemia, not the earliest.
Option B: Option B is incorrect because it places ECG changes first; electrical changes occur after both metabolic and mechanical manifestations have already developed.
Option E: Option E is incorrect because it begins with regional wall motion abnormality, skipping both the metabolic changes and diastolic dysfunction that precede it, and then misorders the remaining steps.
6. A 58-year-old man reports chest pressure that reliably occurs when he walks up two flights of stairs or carries groceries uphill, always resolves within three minutes of resting, and has been unchanged in pattern for eight months. His coronary angiogram reveals a 75% stenosis of the left anterior descending artery. Which of the following best describes the pathophysiological mechanism responsible for his symptoms?
A) Focal coronary artery spasm at the stenosis site producing transient complete occlusion; ischemia occurs at rest because spasm is triggered by circadian variations in sympathetic tone rather than by physical demand
B) Plaque rupture with partial thrombosis creating a dynamic, partially occlusive lesion; symptoms are demand-triggered because the thrombus is non-occlusive at rest but becomes occlusive with increased flow velocity during exertion
C) Fixed atherosclerotic stenosis that limits the capacity to augment coronary blood flow in response to demand; at rest, residual flow through the stenosis is sufficient, but exertion raises heart rate and wall stress to a level at which the fixed supply cannot match escalating demand — producing ischemia at a predictable, reproducible rate-pressure product
D) Microvascular dysfunction with impaired coronary flow reserve throughout the left anterior descending territory; the epicardial stenosis is an incidental finding unrelated to the exertional pattern of symptoms
E) Spontaneous coronary artery dissection causing intermittent compromise of the true lumen; symptoms are exertional because physical activity increases aortic wall shear stress and temporarily worsens the dissection flap
ANSWER: C
Rationale:
This question asked you to identify the pathophysiological mechanism of classic stable exertional angina. Option C is correct: the mechanism is a fixed atherosclerotic stenosis that limits the maximum coronary blood flow achievable through that vessel. At rest, the residual flow through the stenosis (and through any collateral vessels that may have developed) is adequate to meet baseline myocardial oxygen demand. With exertion, heart rate, contractility, and wall stress all increase simultaneously, driving MVO2 upward. When demand reaches the level at which the fixed supply cannot keep pace, ischemia occurs — always at a predictable, reproducible rate-pressure product in a given patient. Relief by rest (within 2–5 minutes) or sublingual nitroglycerin (within 1–3 minutes) is characteristic because both interventions rapidly reduce MVO2 or increase supply without requiring any change in the fixed stenosis itself.
Option A: Option A describes vasospastic (Prinzmetal) angina, which occurs at rest and is associated with transient ST elevation, not the exertional pattern with predictable threshold described here.
Option B: Option B describes unstable angina, in which plaque rupture and superimposed thrombosis create a dynamic lesion with an unpredictable, worsening pattern — the eight-month stable, unchanged pattern in this patient is specifically inconsistent with the dynamic pathology of unstable angina.
Option D: Option D incorrectly attributes the symptoms to microvascular dysfunction while dismissing the 75% epicardial stenosis as incidental; a hemodynamically significant epicardial stenosis is not an incidental finding and is the most parsimonious explanation for exertional ischemia at a predictable threshold.
Option E: Option E describes spontaneous coronary artery dissection (SCAD), which typically presents acutely and is not associated with a prolonged stable exertional pattern; furthermore, the angiogram showing a fixed 75% stenosis is not consistent with SCAD as the mechanism.
7. A 64-year-old woman with known coronary artery disease reports that she develops chest tightness when walking one to two level blocks at a normal pace or climbing one flight of stairs slowly, but has no symptoms at rest. Her activities of daily living are markedly curtailed because she can no longer walk to the corner store or manage her laundry room stairs without stopping. According to the Canadian Cardiovascular Society (CCS) classification of angina severity, which class best describes her symptoms?
A) CCS Class III — marked limitation of ordinary physical activity; angina occurs with walking one to two level blocks on flat ground or climbing one flight of stairs at a normal pace
B) CCS Class I — angina occurs only with strenuous, rapid, or prolonged exertion; ordinary physical activity does not cause symptoms
C) CCS Class II — slight limitation of ordinary activity; angina occurs with brisk walking or climbing stairs rapidly, walking uphill, walking after meals, or in cold weather
D) CCS Class IV — inability to carry on any physical activity without discomfort; anginal symptoms may be present at rest
E) CCS Class II — slight limitation; angina occurs only during activities requiring greater than average effort, such as competitive sports or heavy manual labor
ANSWER: A
Rationale:
This question asked you to correctly classify angina severity using the Canadian Cardiovascular Society (CCS) grading system. Option A is correct: CCS Class III is defined as marked limitation of ordinary physical activity, with angina occurring during walking one to two level blocks at a normal pace or climbing one flight of stairs. This patient's description — symptoms with one to two blocks of flat walking and one flight of stairs, with marked curtailment of daily activities — fits Class III precisely. The CCS classification guides both the intensity of pharmacological therapy and the threshold for revascularization referral; Class III patients typically require optimization of at least two antianginal drug classes and are candidates for revascularization evaluation. Option E also describes CCS Class II but applies an incorrect threshold — Class II is not limited to competitive sports or heavy labor; slight limitation applies to activities somewhat above the sedentary baseline.
Option B: Option B describes CCS Class I, in which angina occurs only with strenuous or unusually demanding exertion — ordinary daily activities do not provoke symptoms. This patient's symptoms are clearly triggered by ordinary activities, excluding Class I.
Option C: Option C describes CCS Class II, which involves slight limitation — symptoms with brisk walking or stair climbing at a faster-than-normal pace, in cold weather, after meals, or with emotional stress. This patient's symptoms occur even at a normal pace and one flight of stairs, which exceeds the Class II threshold and represents a greater degree of limitation.
Option D: Option D describes CCS Class IV, which is characterized by the inability to perform any physical activity without symptoms and the possible presence of angina at rest. This patient explicitly has no symptoms at rest, excluding Class IV.
8. A 44-year-old woman presents with recurrent chest pain that awakens her from sleep between 2 and 4 AM, lasts 5–10 minutes, and resolves spontaneously. She denies any exertional chest pain. An ECG captured during an episode shows transient ST elevation in leads V2–V4 that normalizes once symptoms resolve. Coronary angiography reveals no obstructive stenoses. Which of the following best describes the ECG finding and the underlying mechanism in this patient?
A) Transient ST depression reflecting subendocardial ischemia from increased myocardial oxygen demand during REM sleep, when sympathetic surges raise heart rate and blood pressure
B) Transient ST elevation from spontaneous coronary artery dissection causing intermittent true-lumen compromise; the spontaneous resolution reflects temporary re-apposition of the dissection flap
C) Transient ST depression from microvascular spasm producing heterogeneous subendocardial perfusion; normal epicardial arteries confirm microvascular angina as the diagnosis
D) Transient ST elevation produced by increased LVEDP during sleep compressing subendocardial vessels; angiographically normal arteries confirm diastolic dysfunction rather than epicardial disease
E) Transient ST elevation reflecting transmural ischemia from focal epicardial coronary artery spasm causing near-total or total occlusion; unlike stable exertional angina, myocardial oxygen demand is normal and ischemia is a pure supply-side event
ANSWER: E
Rationale:
This question asked you to identify the correct ECG pattern and mechanism of vasospastic (Prinzmetal or variant) angina. Option E is correct: vasospastic angina produces transient ST elevation, not depression, because focal epicardial spasm causes near-total or total occlusion of the affected artery — producing transmural (full-thickness) ischemia rather than the subendocardial ischemia of demand-driven stable angina. Critically, myocardial oxygen demand is normal; this is a pure supply-side failure, mechanistically distinct from stable exertional angina. Additional features — rest-onset symptoms, circadian pattern (early morning, when sympathetic tone and coronary vasomotor reactivity peak), and resolution on sublingual nitroglycerin — complete the picture. Angiographically normal coronary arteries are consistent with vasospasm, as spasm can occur on arteries without obstructive plaque.
Option A: Option A describes ST depression and attributes symptoms to demand increases during REM sleep — this would produce the ECG pattern of demand-driven subendocardial ischemia, not the transient ST elevation documented in this case.
Option B: Option B inverts the ST direction (correctly noting ST elevation) but misidentifies the mechanism as spontaneous coronary artery dissection; SCAD does not typically present with a chronic, recurrent, self-terminating nocturnal pattern over multiple episodes and would not repeatedly resolve spontaneously.
Option C: Option C describes microvascular angina, which is associated with ST depression (subendocardial heterogeneous ischemia), not ST elevation, and presents with exertional or mixed symptoms rather than this pure rest-onset nocturnal pattern.
Option D: Option D incorrectly attributes transmural ST elevation to elevated LVEDP compressing subendocardial vessels — this mechanism would cause subendocardial ischemia with ST depression, not ST elevation; ST elevation requires near-total transmural supply failure, not compressive subendocardial effects.
9. A 55-year-old post-menopausal woman with hypertension and type 2 diabetes reports typical exertional chest pressure. Her exercise stress test is positive. Coronary angiography reveals no obstructive stenoses. A subsequent positron emission tomography (PET) perfusion study demonstrates a coronary flow reserve (CFR) of 1.7. Which of the following best identifies her diagnosis and its fundamental pathophysiological mechanism?
A) Vasospastic angina — focal epicardial spasm intermittently triggered by exertion; CFR is reduced because spasm episodes coincide with the pharmacological stress agent used during PET imaging
B) Microvascular angina — the resistance vessels of the coronary microvasculature (less than 500 microns in diameter) cannot adequately dilate in response to increased demand, impairing CFR below 2.0 and producing subendocardial ischemia despite normal epicardial arteries
C) Stable exertional angina with false-negative angiography — the 75% stenosis responsible for her symptoms was missed on angiography; CFR below 2.0 confirms hemodynamically significant obstructive disease
D) Syndrome of inappropriate sinus tachycardia — her exertional symptoms are caused by rate-related diastolic dysfunction rather than true ischemia; reduced CFR reflects impaired diastolic filling rather than microvascular pathology
E) Non-obstructive atherosclerosis with endothelial dysfunction — her normal CFR threshold should be recalculated using age- and sex-specific norms, as post-menopausal women have a lower normal CFR range than the standard cutoff of 2.0
ANSWER: B
Rationale:
This question asked you to identify microvascular angina and its mechanism. Option B is correct: microvascular angina (also called Cardiac Syndrome X) results from dysfunction of the coronary microvasculature — specifically the resistance vessels less than 500 microns in diameter that are responsible for autoregulating coronary blood flow. The fundamental abnormality is impaired coronary flow reserve (CFR): the microvasculature cannot adequately dilate in response to increased myocardial oxygen demand, producing subendocardial ischemia despite angiographically normal epicardial coronary arteries. A CFR below 2.0 on functional imaging (PET, cardiac MRI, or intracoronary wire) confirms the diagnosis. This condition is particularly prevalent in post-menopausal women and patients with hypertension, diabetes, and left ventricular hypertrophy — all features present in this patient.
Option A: Option A describes vasospastic angina, which is a rest-onset syndrome rather than an exertional one and is associated with transient ST elevation rather than a reduced CFR on stress perfusion imaging; CFR impairment in vasospastic angina is not the primary mechanism and would not present this way.
Option C: Option C is incorrect because a CFR of 1.7 on PET does not indicate a missed epicardial stenosis; microvascular CFR reduction is measured at the level of the microvasculature and can occur independently of any epicardial obstruction. Falsely negative angiography for significant stenoses does occur but is not the explanation when microvascular functional testing directly identifies the mechanism.
Option D: Option D incorrectly attributes her findings to sinus tachycardia; sinus tachycardia would not produce a positive stress test with a reduced CFR of 1.7 in the absence of any rate abnormality described in the case.
Option E: Option E is incorrect because CFR below 2.0 is not subject to sex-specific recalibration in clinical practice; a CFR of 1.7 is abnormal regardless of age and sex, and redefining the normal threshold to dismiss the finding would be clinically inappropriate.
10. Organic nitrates have been used to treat angina for over 150 years. At standard clinical doses, which of the following best describes their primary hemodynamic mechanism of action and explains why this mechanism reduces myocardial oxygen demand?
A) Nitrates at standard doses primarily dilate epicardial coronary arteries, increasing oxygen supply by improving flow through stenotic segments and collateral vessels, with minimal effect on preload or afterload
B) Nitrates at standard doses primarily reduce afterload by dilating arterioles throughout the systemic circulation, decreasing left ventricular systolic wall stress and reducing MVO2 at the point of peak pressure generation
C) Nitrates at standard doses exert their primary anti-ischemic effect by directly inhibiting cardiac beta-1 adrenoceptors, reducing heart rate and contractility and thereby lowering MVO2
D) Nitrates at standard doses primarily dilate large capacitance veins throughout the systemic circulation, reducing venous return to the right heart, lowering left ventricular end-diastolic pressure and volume, decreasing ventricular wall stress via the Law of Laplace, and improving subendocardial perfusion by reducing the compressive forces on subendocardial vessels
E) Nitrates at standard doses primarily act on pulmonary vasculature, reducing right ventricular afterload and improving cardiac output, with the reduction in MVO2 occurring indirectly through improved left ventricular filling
ANSWER: D
Rationale:
This question asked you to identify the primary hemodynamic mechanism of organic nitrates at standard clinical doses. Option D is correct: nitrates at standard doses act predominantly on large capacitance veins (the venous reservoir), producing venodilation that reduces venous return to the right heart. This decreases right atrial pressure, right ventricular filling, and ultimately left ventricular end-diastolic pressure (LVEDP) and end-diastolic volume. By the Law of Laplace, reduced end-diastolic volume decreases ventricular radius, lowering wall stress and MVO2. The reduction in LVEDP also improves subendocardial perfusion by reducing the compressive forces that the distended ventricle exerts on subendocardial vessels. This preload reduction is the primary anti-ischemic mechanism at standard doses; large capacitance veins are the primary target because they contain the largest proportion of the circulating blood volume.
Option A: Option A describes coronary vasodilation — while nitrates do dilate epicardial coronary arteries and this contributes to their efficacy, particularly in vasospastic angina, it is not the primary mechanism at standard antianginal doses; the dominant effect is venodilation and preload reduction.
Option B: Option B describes afterload reduction via arteriolar dilation — this does become a significant mechanism at higher nitrate doses (greater than 100 mcg/min intravenously), but at standard doses, the veins are far more sensitive to nitrate-mediated relaxation than the arterioles, and preload reduction precedes and dominates over afterload reduction.
Option C: Option C is incorrect: nitrates have no direct action on cardiac beta-1 adrenoceptors; their mechanism is entirely through smooth muscle relaxation via NO-cGMP pathway, with no direct effect on heart rate or contractility.
Option E: Option E is incorrect: nitrates do not act primarily on the pulmonary vasculature, and their mechanism does not operate via improvement in right ventricular function; the primary target is the systemic venous circulation.
11. Among the four pharmacological levers available in antianginal therapy — preload reduction, afterload reduction, heart rate reduction, and coronary vasodilation — which is considered the most powerful single anti-ischemic intervention, and what is the specific reason it surpasses the others?
A) Afterload reduction, because lowering systolic wall stress reduces the largest single component of MVO2 and simultaneously increases stroke volume, improving cardiac efficiency without any direct effect on the coronary vasculature
B) Preload reduction, because lowering LVEDP reduces wall stress via the Law of Laplace and simultaneously decompresses subendocardial vessels, addressing both the demand and the perfusion components of ischemia in a single mechanism
C) Heart rate reduction, because slowing the heart simultaneously reduces MVO2 by decreasing the number of oxygen-consuming cycles per minute and prolongs diastole — the phase during which the left ventricle is perfused — thereby improving coronary blood flow at the same time that demand is falling
D) Coronary vasodilation, because directly increasing the diameter of stenotic epicardial arteries and collateral vessels raises oxygen delivery to the ischemic zone regardless of the level of demand, addressing the supply side without any compromise to cardiac output
E) Contractility reduction, because decreasing the force of each contraction reduces cross-bridge cycling and ATP hydrolysis more efficiently than any other intervention, and this effect is independent of heart rate or loading conditions
ANSWER: C
Rationale:
This question asked you to identify the most powerful single anti-ischemic pharmacological lever and explain why it holds that rank. Option C is correct: heart rate reduction surpasses other interventions because it simultaneously improves both sides of the oxygen balance equation. On the demand side, reducing heart rate decreases the number of oxygen-consuming cardiac cycles per minute, with a near-proportional reduction in MVO2. On the supply side, slower heart rate prolongs diastole, which is the phase during which the left ventricle receives its blood supply — longer diastole means more time for coronary perfusion with each beat. No other pharmacological lever carries this dual benefit: preload and afterload reduction address demand only; coronary vasodilation addresses supply only; contractility reduction addresses demand only. The dual supply-demand benefit of heart rate reduction is the basis for ranking it as the most powerful single anti-ischemic intervention and the primary target of both beta-blockers and non-dihydropyridine calcium channel blockers in angina management.
Option A: Option A describes afterload reduction correctly but overstates its ranking; it does not carry a supply-side benefit and its MVO2 reduction, while real, is not as dominant as the combined effect of heart rate reduction.
Option B: Option B describes preload reduction correctly — LVEDP reduction does decompress subendocardial vessels and has a supply component — but its supply benefit is less direct and less powerful than the diastolic filling time benefit of heart rate reduction.
Option D: Option D describes coronary vasodilation correctly but this mechanism is supply-only; it does nothing to reduce demand, and its efficacy is limited by the degree of fixed stenosis and the extent of spasm-driven disease.
Option E: Option E overstates contractility reduction as the most efficient lever; while contractility reduction does decrease MVO2, beta-blockers, which reduce contractility, exert most of their anti-ischemic benefit through heart rate reduction, and isolated contractility reduction without rate reduction is a less dominant effect.
12. A 38-year-old woman is diagnosed with vasospastic (Prinzmetal) angina confirmed by acetylcholine provocation testing. A colleague suggests starting metoprolol succinate for its cardioprotective properties. Which of the following best explains why beta-blockers are contraindicated in vasospastic angina, and whether this contraindication applies to cardioselective agents such as metoprolol?
A) Beta-blockers are contraindicated in vasospastic angina because they reduce heart rate below the minimum needed to maintain adequate coronary perfusion pressure during spasm episodes; cardioselective agents have less bradycardic effect and are therefore acceptable at low doses
B) Beta-blockers are contraindicated in vasospastic angina because blockade of beta-2 adrenoceptors on coronary smooth muscle removes the normal vasodilatory tone mediated by this receptor subtype, leaving alpha-1-mediated vasoconstriction unopposed and potentially precipitating or worsening coronary spasm; this is a class effect that applies to all beta-blockers, including cardioselective agents such as metoprolol
C) Beta-blockers are contraindicated in vasospastic angina because they increase myocardial oxygen demand by causing reflex tachycardia; cardioselective agents avoid this complication by sparing beta-2 receptors in the peripheral vasculature
D) Beta-blockers are contraindicated in vasospastic angina only when combined with calcium channel blockers; used as monotherapy, metoprolol is an acceptable second-line agent if calcium channel blockers are not tolerated
E) Beta-blockers are relatively contraindicated in vasospastic angina because they reduce cardiac output, lowering coronary perfusion pressure; this effect is less pronounced with cardioselective agents, which may be used cautiously in patients with preserved ventricular function
ANSWER: B
Rationale:
This question asked you to identify the correct mechanism of the beta-blocker contraindication in vasospastic angina and whether cardioselective agents are exempt. Option B is correct: beta-2 adrenoceptors on coronary vascular smooth muscle normally mediate vasodilation in response to catecholamine stimulation. When beta-blockers block these receptors, this vasodilatory tone is removed. The remaining adrenergic input to the coronary vasculature is through alpha-1 receptors, which mediate vasoconstriction — and these receptors are now unopposed. This pharmacological imbalance can precipitate or worsen coronary artery spasm. Critically, this is a class effect: it applies to all beta-blockers, including cardioselective agents such as metoprolol and atenolol. Cardioselectivity refers to preferential beta-1 blockade at low doses, but beta-1 selectivity is relative and incomplete — at therapeutic doses, cardioselective agents retain meaningful beta-2 blocking activity, and even partial beta-2 blockade in the coronary vasculature carries the same risk of unopposed alpha-1 vasoconstriction.
Option A: Option A incorrectly attributes the contraindication to bradycardia-mediated perfusion failure rather than to the receptor mechanism; while severe bradycardia can reduce coronary perfusion, this is not the reason beta-blockers are specifically contraindicated in vasospastic angina.
Option C: Option C inverts the mechanism entirely — beta-blockers slow heart rate (reducing MVO2) and do not cause reflex tachycardia; reflex tachycardia is a concern with vasodilating agents such as dihydropyridine CCBs, not with beta-blockers.
Option D: Option D incorrectly states that the contraindication is limited to combination use; beta-blockers are contraindicated in vasospastic angina as monotherapy as well as in combination.
Option E: Option E describes a relative rather than absolute contraindication based on cardiac output reduction, which mischaracterizes the nature and mechanism of the contraindication; the contraindication is mechanistic (receptor imbalance), not hemodynamic, and applies regardless of ventricular function.
13. A 67-year-old man presents to the emergency department with an inferior ST-elevation myocardial infarction (STEMI). He is diaphoretic and hypotensive with a blood pressure of 82/54 mmHg. A junior resident prepares to administer sublingual nitroglycerin for ongoing chest pain. Which of the following best explains why nitroglycerin is specifically contraindicated in this setting, and what should be done before administering any nitrate in inferior STEMI?
A) Nitroglycerin is contraindicated when right ventricular infarction is present because the failing right ventricle depends on elevated filling pressures (preload) to generate adequate forward output across the pulmonary circulation; nitrate-induced venodilation reduces venous return and right ventricular preload, precipitating severe hypotension and hemodynamic collapse — right ventricular involvement must be excluded by right-sided ECG leads (ST elevation in V4R) before any nitrate is administered in inferior STEMI
B) Nitroglycerin is contraindicated in inferior STEMI because its coronary vasodilating effect preferentially increases flow to the non-infarcted territory, producing a coronary steal syndrome that worsens ischemia in the inferior distribution
C) Nitroglycerin is contraindicated in hypotensive patients with inferior STEMI because it directly suppresses sinus node automaticity, worsening the bradycardia that frequently accompanies inferior MI and compounding the hemodynamic instability
D) Nitroglycerin is contraindicated in all STEMI presentations because it activates the renin-angiotensin system, causing reflex vasoconstriction that counteracts its vasodilatory effect and raises myocardial oxygen demand above baseline
E) Nitroglycerin is contraindicated in inferior STEMI because inferior MI invariably involves the left ventricular posterior wall, and nitrate-induced afterload reduction paradoxically increases left ventricular end-diastolic volume in this territory, worsening subendocardial ischemia
ANSWER: A
Rationale:
This question asked you to identify the specific contraindication to nitroglycerin in the context of inferior STEMI and describe the required safety step before administration. Option A is correct: right ventricular infarction is a specific and critical contraindication to nitrates in the acute setting. The right ventricle, when infarcted, loses contractile function and becomes entirely dependent on high filling pressures (preload) to generate adequate forward output through the pulmonary circulation to reach the left heart. Nitrate-induced venodilation reduces venous return, dropping right ventricular preload precipitously — in a preload-dependent right ventricle, this can cause immediate severe hypotension and hemodynamic collapse. Right ventricular involvement occurs in approximately 30–50% of inferior STEMIs because the right coronary artery (which supplies the inferior wall of the left ventricle in right-dominant circulation) also supplies the right ventricle in most patients. Before administering any nitrate in an inferior STEMI, right-sided ECG leads must be obtained and ST elevation in V4R specifically sought; in confirmed right ventricular infarction, treatment of hypotension is volume loading to restore right ventricular preload, not vasodilation. Option E is anatomically incorrect: nitrate-induced afterload reduction does not paradoxically increase LVEDV; reducing afterload decreases wall stress and typically reduces LVEDV by improving ventricular emptying.
Option B: Option B describes a coronary steal mechanism; while coronary steal is a theoretical concern with some vasodilators in certain anatomical configurations, it is not the established primary contraindication to nitrates in inferior STEMI.
Option C: Option C is incorrect: nitroglycerin does not directly suppress sinus node automaticity; its action is entirely on vascular smooth muscle via the NO-cGMP pathway, not on cardiac conduction tissue.
Option D: Option D is incorrect: nitroglycerin does not activate the renin-angiotensin system as a primary mechanism and is not contraindicated in all STEMI; intravenous nitroglycerin is in fact a Class I indication in STEMI with persistent ischemia, pulmonary congestion, or hypertension when RV infarction is excluded.
14. A 61-year-old man with stable angina presents to the emergency department with chest pain of 30 minutes duration. Before administering sublingual nitroglycerin, the triage nurse asks about recent medication use. The patient acknowledges taking sildenafil approximately 18 hours earlier. Which of the following best explains why this information is critically important and what the mechanism of the interaction is?
A) Sildenafil increases hepatic CYP3A4 activity, accelerating the metabolism of nitroglycerin to inactive metabolites and rendering the nitrate ineffective for symptom relief; a higher dose of nitroglycerin is required to overcome this interaction
B) Sildenafil competes with nitroglycerin for binding to soluble guanylate cyclase in vascular smooth muscle, blocking the NO-cGMP vasodilation pathway and preventing any hemodynamic effect from the nitrate
C) Sildenafil sensitizes alpha-1 adrenoceptors in the systemic vasculature to norepinephrine; when nitroglycerin is added, the competing vasodilatory stimulus triggers a baroreceptor reflex that causes paradoxical hypertension and reflex tachycardia
D) Sildenafil inhibits phosphodiesterase type 3 (PDE-3) in cardiac myocytes, increasing cAMP and raising heart rate and contractility; when nitroglycerin reduces preload, the combined hemodynamic effect produces myocardial ischemia rather than relieving it
E) Sildenafil inhibits phosphodiesterase type 5 (PDE-5), which is the enzyme that degrades cyclic GMP (cGMP) in vascular smooth muscle; nitroglycerin increases cGMP production via the NO-soluble guanylate cyclase pathway, and when PDE-5 is simultaneously blocked, cGMP accumulates to levels that produce catastrophic systemic vasodilation and severe, potentially fatal hypotension
ANSWER: E
Rationale:
This question asked you to explain the mechanism of the PDE-5 inhibitor — nitrate interaction and its clinical significance. Option E is correct: sildenafil (and vardenafil and tadalafil) inhibits phosphodiesterase type 5 (PDE-5), the enzyme responsible for degrading cyclic GMP (cGMP) in vascular smooth muscle. Organic nitrates, via their release of nitric oxide (NO), activate soluble guanylate cyclase, which converts GTP to cGMP. cGMP activates protein kinase G, leading to smooth muscle relaxation and vasodilation. When PDE-5 is simultaneously blocked by a PDE-5 inhibitor, the cGMP produced by the nitrate cannot be degraded — it accumulates to concentrations that produce severe, uncontrolled systemic vasodilation and catastrophic hypotension. This interaction is an absolute contraindication: nitrates must not be administered within 24 hours of sildenafil or vardenafil use, and within 48 hours of tadalafil use (due to its longer half-life). In this case, 18 hours have elapsed since sildenafil use — still within the 24-hour contraindication window. Nitroglycerin must not be given, and the team must evaluate alternative antianginal measures.
Option A: Option A inverts the interaction: sildenafil does not induce CYP3A4 and does not accelerate nitroglycerin metabolism; its effect on the shared signaling pathway goes in the opposite direction — potentiation, not attenuation.
Option B: Option B is incorrect: sildenafil does not compete with nitroglycerin for guanylate cyclase binding; PDE-5 acts downstream of cGMP production, not at the guanylate cyclase level, and blocking PDE-5 potentiates rather than blocks the NO-cGMP pathway.
Option C: Option C is incorrect: sildenafil has no action on alpha-1 adrenoceptors and does not cause baroreceptor-mediated paradoxical hypertension; the hemodynamic consequence of the combination is hypotension, not hypertension.
Option D: Option D confuses PDE-5 with PDE-3: PDE-3 is the cardiac isoform that degrades cAMP; sildenafil is selective for PDE-5 and has no clinically significant PDE-3 inhibitory activity at therapeutic doses; furthermore, the direction of the hemodynamic consequence is again hypotension, not ischemia from increased demand.
15. A 55-year-old man with stable angina is started on amlodipine monotherapy. His chest pain frequency initially improves, but he reports new-onset palpitations and his resting heart rate has increased from 68 to 84 beats per minute. Which of the following best explains the mechanism responsible for the heart rate increase and identifies the pharmacological lever that amlodipine acts on most directly in angina?
A) Amlodipine primarily reduces heart rate via SA node L-type calcium channel blockade; the increase in heart rate reflects a paradoxical autonomic response seen specifically with long-acting dihydropyridines and not with shorter-acting agents
B) Amlodipine primarily reduces MVO2 by inhibiting cardiac beta-1 adrenoceptors, and the heart rate increase reflects upregulation of these receptors in response to prolonged blockade — a mechanism similar to beta-blocker withdrawal
C) Amlodipine's primary anti-ischemic mechanism is preload reduction via coronary venodilation; heart rate increases because reduced preload lowers stroke volume, triggering a compensatory baroreceptor-mediated tachycardia
D) Amlodipine acts primarily on the afterload lever — blocking L-type calcium channels in peripheral arteriolar smooth muscle reduces systemic vascular resistance and lowers left ventricular systolic wall stress; the resulting fall in blood pressure triggers a baroreceptor-mediated reflex tachycardia that increases MVO2, which is why amlodipine is typically combined with a beta-blocker to suppress this reflex
E) Amlodipine acts primarily on the coronary vasodilation lever by blocking L-type channels in epicardial coronary smooth muscle; heart rate increases because improved coronary supply reduces sympathetic nervous system activation, and lower sympathetic tone paradoxically raises the intrinsic SA node firing rate
ANSWER: D
Rationale:
This question asked you to identify the primary anti-anginal mechanism of dihydropyridine (DHP) calcium channel blockers and explain the heart rate increase that limits their use as monotherapy. Option D is correct: amlodipine (and other DHP-CCBs such as nifedipine and felodipine) acts primarily on peripheral arteriolar smooth muscle, blocking L-type calcium channels to produce vasodilation. This reduces systemic vascular resistance, lowering afterload and decreasing left ventricular systolic wall stress — the afterload pharmacological lever. The fall in arterial blood pressure activates baroreceptors in the aortic arch and carotid sinus, which trigger a compensatory increase in sympathetic outflow. This reflex tachycardia increases heart rate and contractility, partially counteracting the anti-ischemic benefit and, in susceptible patients, potentially worsening angina. This is why DHP-CCBs are typically combined with a beta-blocker in angina: the beta-blocker suppresses the reflex tachycardia and blunts the sympathetic surge, while the DHP-CCB contributes afterload reduction and coronary vasodilation — each agent addressing what the other cannot. Option E contains a correct partial statement (amlodipine does vasodilate coronary smooth muscle) but misidentifies coronary vasodilation as the primary mechanism and gives an anatomically implausible explanation for the tachycardia; the reflex tachycardia is baroreceptor-mediated in response to arterial pressure reduction, not a consequence of improved coronary supply.
Option A: Option A is incorrect because amlodipine does not reduce heart rate; DHP-CCBs have minimal direct effect on the SA node (that property belongs to non-DHP CCBs such as diltiazem and verapamil). The heart rate increase described is not paradoxical — it is the expected reflex response to vasodilation.
Option B: Option B is incorrect: amlodipine has no beta-adrenergic receptor activity and does not cause receptor upregulation of any kind; its mechanism is entirely through L-type calcium channel blockade in smooth muscle.
Option C: Option C incorrectly identifies the primary mechanism as preload reduction via venodilation; DHP-CCBs act on arteriolar smooth muscle (afterload), not on capacitance veins (preload); venodilation causing reduced preload is the mechanism of organic nitrates, not DHP-CCBs.
16. A 60-year-old man with CCS Class II stable angina is inadequately controlled on metoprolol succinate 100 mg daily. His resting heart rate is 58 bpm and his blood pressure is 138/84 mmHg. His physician plans to add a second antianginal agent. Which of the following combinations is preferred, and what is the pharmacological rationale for this choice?
A) Add verapamil — the combination of a beta-blocker and a non-dihydropyridine calcium channel blocker is preferred because both agents reduce heart rate and contractility, producing additive suppression of MVO2 at doses lower than either would require alone
B) Add isosorbide mononitrate — the combination of a beta-blocker and a long-acting nitrate is the preferred first addition because nitrates directly dilate stenotic coronary segments while the beta-blocker maintains heart rate control, achieving both supply and demand reduction simultaneously
C) Add amlodipine — a dihydropyridine calcium channel blocker is the preferred addition to a beta-blocker because the beta-blocker suppresses the reflex tachycardia triggered by amlodipine-induced vasodilation, while amlodipine contributes afterload reduction and coronary vasodilation without adding to the AV conduction depression already produced by the beta-blocker
D) Add ranolazine — ranolazine is the preferred second agent in stable angina because it reduces late sodium current (late INa), decreasing intracellular calcium overload and improving diastolic function at the same time that the beta-blocker reduces MVO2, providing complementary metabolic and hemodynamic anti-ischemic effects
E) Add diltiazem — diltiazem is preferred over amlodipine as the second agent because its additional SA node suppression compounds the heart rate reduction achieved by the beta-blocker, making the combination more potent than any other two-drug regimen at equivalent doses
ANSWER: C
Rationale:
This question asked you to identify the preferred first combination in stable angina inadequately controlled on a beta-blocker and explain the pharmacological rationale. Option C is correct: the preferred first combination is a beta-blocker plus a dihydropyridine (DHP) calcium channel blocker such as amlodipine. The pharmacological rationale rests on complementarity: the beta-blocker contributes heart rate reduction, contractility reduction, and suppression of the baroreceptor-mediated reflex tachycardia that DHP-CCBs trigger through their vasodilatory effect on blood pressure. The DHP-CCB contributes afterload reduction and coronary smooth muscle relaxation. Critically, DHP-CCBs have minimal direct effect on the AV node, so adding amlodipine to a beta-blocker does not further depress AV conduction — a safety advantage over combining a beta-blocker with a non-DHP CCB. Each agent in the combination addresses pharmacological levers that the other does not, achieving greater total MVO2 reduction at lower doses of each individual drug.
Option A: Option A describes the combination of a beta-blocker with a non-dihydropyridine CCB (verapamil) — this combination is specifically avoided because both agents depress AV conduction and SA node automaticity; the additive effect can cause dangerous bradycardia, heart block, and hemodynamic compromise, particularly in patients with any pre-existing conduction disease.
Option B: Option B describes beta-blocker plus long-acting nitrate, which is a reasonable third-line addition (completing triple conventional therapy for CCS III–IV) but is not the preferred first addition when a second agent is needed; the DHP-CCB is the preferred second agent before long-acting nitrates in most guideline frameworks.
Option D: Option D describes ranolazine, which is a non-hemodynamic agent (late INa inhibitor) recommended when hemodynamic targets have already been reached but symptoms persist — it is not the preferred second agent when there is still room to optimize hemodynamic therapy.
Option E: Option E describes the combination of beta-blocker plus diltiazem (a non-DHP CCB), which is explicitly avoided for the same reason as verapamil — additive SA node and AV node depression — making this a more dangerous combination than beta-blocker plus DHP-CCB.
17. A 70-year-old woman with known three-vessel coronary artery disease and stable angina develops rapid atrial fibrillation with a ventricular rate of 138 bpm. She promptly develops severe chest pressure at rest despite having had no angina for weeks on her current regimen. Her attending explains that tachycardia is particularly dangerous in patients with coronary artery disease because it impairs myocardial oxygenation through two simultaneous mechanisms. Which of the following correctly identifies both mechanisms?
A) Tachycardia increases MVO2 by raising systolic blood pressure and simultaneously reduces supply by causing reflex coronary vasoconstriction via sympathetic activation of alpha-1 receptors in the coronary vasculature
B) Tachycardia increases MVO2 by multiplying the number of oxygen-consuming cardiac cycles per minute and simultaneously reduces coronary oxygen supply by disproportionately shortening diastole — the phase during which the left ventricle receives the majority of its coronary blood flow — thereby decreasing total coronary perfusion time per minute
C) Tachycardia increases MVO2 by elevating left ventricular end-diastolic pressure and simultaneously reduces supply by compressing subendocardial vessels through increased wall stress, with both effects mediated entirely through preload elevation
D) Tachycardia increases MVO2 by raising contractility through the Bowditch effect (force-frequency relationship) and simultaneously reduces supply by increasing oxygen extraction to near-maximal levels, leaving no extraction reserve during episodes of increased demand
E) Tachycardia increases MVO2 solely through heart rate-mediated increases in cardiac output, while the reduction in supply occurs through decreased aortic diastolic pressure caused by the shortened diastolic filling period reducing stroke volume and lowering diastolic runoff pressure
ANSWER: B
Rationale:
This question asked you to identify both mechanisms by which tachycardia simultaneously impairs myocardial oxygenation. Option B is correct and identifies both mechanisms precisely: on the demand side, each cardiac cycle consumes energy, so increasing heart rate directly multiplies total myocardial oxygen consumption — doubling heart rate nearly doubles MVO2. On the supply side, at higher heart rates, the cardiac cycle shortens disproportionately in its diastolic component: systole shortens relatively little with increasing rate, but diastole shortens substantially. Since the left ventricle receives its coronary blood supply predominantly during diastole (the compressive forces of systole largely prevent left coronary perfusion during that phase), a shorter diastole means less total coronary perfusion time per minute even if each individual beat still delivers some flow. Together, these two mechanisms explain why even brief, moderate tachycardia can precipitate angina in a patient with significant coronary disease who is otherwise well-controlled at rest. Option A correctly identifies sympathetic activation as a mechanism but incorrectly specifies reflex coronary vasoconstriction as the supply-side mechanism; while some alpha-1-mediated coronary vasoconstriction does occur with sympathetic activation, the dominant and direct supply-side mechanism of tachycardia in this context is diastolic time reduction, not active vasoconstriction. Option D correctly notes that the Bowditch (force-frequency) relationship does increase contractility with tachycardia, contributing to MVO2, but incorrectly identifies the supply-side mechanism as exhaustion of oxygen extraction reserve; the supply impairment from tachycardia is a problem of perfusion time (diastolic shortening), not extraction capacity. Option E overly simplifies the demand-side mechanism to cardiac output increase and proposes an indirect aortic pressure mechanism for supply reduction; while aortic diastolic pressure does influence coronary perfusion pressure, the direct and clinically primary supply-side mechanism of tachycardia is diastolic time reduction, not a reduction in diastolic aortic pressure.
Option C: Option C incorrectly attributes both mechanisms entirely to preload elevation; while tachycardia can modestly raise LVEDP, this is not the primary mechanism, and the demand-side effect of increased cycle frequency is independent of preload.
18. A 41-year-old man is newly diagnosed with vasospastic angina confirmed by acetylcholine provocation testing with provocable ST elevation and chest pain. He has no obstructive coronary artery disease. Which drug class is first-line treatment, and what is the pharmacological rationale for its efficacy in this specific angina subtype?
A) Calcium channel blockers are first-line because they directly inhibit the pathological calcium-mediated smooth muscle hyperreactivity in the coronary vessel wall responsible for spasm — blocking L-type calcium channels in coronary smooth muscle prevents the excessive calcium influx that drives vasospasm, addressing the supply-side failure at its root mechanism
B) Beta-blockers are first-line because vasospastic angina, like stable exertional angina, is ultimately triggered by elevated sympathetic tone; blocking cardiac beta-1 receptors reduces heart rate and the oxygen demand that precipitates spasm episodes
C) Long-acting organic nitrates are first-line because their sustained venodilatory effect maintains reduced coronary vascular tone throughout the day, preventing the transient vasoconstrictor surges that trigger spasm
D) Aspirin is first-line because vasospastic angina is driven by platelet aggregation at sites of endothelial injury; thromboxane A2 released from activated platelets is the primary vasoconstrictor mediating spasm in most patients
E) Ranolazine is first-line because its inhibition of the late sodium current (late INa) reduces intracellular calcium overload in coronary smooth muscle — the same mechanism responsible for vasospasm — more selectively than calcium channel blockers
ANSWER: A
Rationale:
This question asked you to identify the first-line treatment for vasospastic angina and explain the mechanism. Option A is correct: calcium channel blockers (CCBs) are first-line for vasospastic angina because they directly inhibit the pathological calcium-mediated smooth muscle hyperreactivity that causes spasm. In vasospastic angina, the coronary smooth muscle is hyperreactive to vasoconstrictors — endothelin-1, serotonin, histamine, and alpha-adrenergic stimulation — and endothelial nitric oxide bioavailability is reduced. Blocking L-type calcium channels in coronary smooth muscle prevents the excessive calcium influx that drives vasoconstriction, directly addressing the supply-side failure. Both dihydropyridine and non-dihydropyridine CCBs are effective; long-acting formulations are preferred to maintain 24-hour protection. Because vasospastic angina is a pure supply-side disorder with normal MVO2, demand-reduction strategies are physiologically irrelevant as primary therapy, which is why CCBs (supply-focused) rather than beta-blockers (demand-focused) are first-line.
Option B: Option B describes beta-blockers and is incorrect for two reasons: first, the mechanism is wrong — vasospastic angina is not triggered by elevated oxygen demand but by spontaneous smooth muscle hyperreactivity; second, beta-blockers are specifically contraindicated in vasospastic angina because beta-2 blockade leaves alpha-1-mediated vasoconstriction unopposed, potentially worsening spasm.
Option C: Option C describes long-acting nitrates, which are a second-line agent in vasospastic angina (added when CCBs alone are insufficient) but not first-line; nitrates dilate epicardial coronary arteries via NO-cGMP pathway but do not address the underlying smooth muscle hyperreactivity as directly as CCBs.
Option D: Option D is incorrect: platelet-derived thromboxane A2 may contribute to vasoconstriction at sites of endothelial injury, but antiplatelet therapy is not the primary treatment for vasospastic angina; the fundamental mechanism is smooth muscle hyperreactivity, not platelet aggregation.
Option E: Option E is incorrect: ranolazine inhibits the late sodium current in cardiac myocytes, not coronary smooth muscle, and is not established as first-line for vasospastic angina; CCBs remain the pharmacological cornerstone for this indication.
19. A 52-year-old post-menopausal woman with microvascular angina reports that her chest pain paradoxically worsens within minutes of taking sublingual nitroglycerin, despite the fact that nitroglycerin reliably relieves her colleague's stable exertional angina within 90 seconds. Which of the following best explains why nitroglycerin may worsen rather than relieve symptoms in microvascular angina?
A) Nitroglycerin is ineffective in microvascular angina because the microvasculature lacks soluble guanylate cyclase; without this enzyme, NO cannot generate cGMP in resistance vessels and therefore has no vasodilatory effect in the microvascular territory
B) Nitroglycerin worsens microvascular angina by activating cardiac sympathetic afferents in the microvasculature through a direct nitric oxide receptor interaction, triggering a reflex increase in heart rate and contractility that raises MVO2 above the pre-treatment level
C) Nitroglycerin reduces preload so effectively in microvascular angina patients that LVEDP falls below the minimum required for adequate subendocardial perfusion pressure; the resulting reduction in coronary perfusion pressure worsens ischemia
D) Nitroglycerin worsens microvascular angina because it preferentially dilates the coronary microvasculature while leaving epicardial vessels constricted; the resulting reversal of the normal pressure gradient causes retrograde flow toward the epicardium
E) Nitroglycerin preferentially dilates larger epicardial coronary vessels and proximal resistance arteries while having a less predictable effect on the microvasculature; in some patients this may create a microvascular steal phenomenon, shunting blood flow toward epicardial and non-ischemic territories and away from the already-compromised subendocardial microvascular zones
ANSWER: E
Rationale:
This question asked you to explain why sublingual nitroglycerin may paradoxically worsen symptoms in microvascular angina. Option E is correct: organic nitrates preferentially dilate large capacitance veins (at standard doses) and epicardial coronary arteries, but their effect on the microvasculature (vessels less than 500 microns in diameter that are the resistance vessels of the coronary circulation) is less predictable and less reliable. In microvascular angina, where the fundamental problem is impaired microvascular dilation in response to demand, nitroglycerin may dilate larger vessels upstream without proportionately dilating the resistance microvasculature. This can produce a steal phenomenon: blood flow preferentially moves into the path of least resistance (the now-dilated larger vessels and non-ischemic territories), potentially diverting flow away from the already-compromised subendocardial microvascular zones. The clinical consequence is worsening symptoms rather than relief. This is clinically important: the response to sublingual nitroglycerin is not a reliable diagnostic test for angina subtype — absent or paradoxical response does not exclude coronary disease and does not rule out ischemia. Option A is pharmacologically incorrect: the microvasculature does contain soluble guanylate cyclase and does respond to NO; the issue in microvascular angina is not an absence of the NO-cGMP pathway but rather an abnormal relationship between nitrate-induced dilation of different vessel sizes. Option C is a plausible-sounding mechanism but not the established explanation; while profound preload reduction can theoretically reduce coronary perfusion pressure in some settings, this does not specifically explain the paradoxical response in microvascular angina, and the degree of preload reduction from a standard sublingual nitroglycerin dose does not typically reduce coronary perfusion pressure to ischemic levels in patients with normal or near-normal left ventricular function.
Option B: Option B is incorrect: nitroglycerin does not activate cardiac sympathetic afferents through a direct nitric oxide receptor interaction; reflex tachycardia from nitroglycerin occurs via baroreceptor activation in response to hypotension, not via a direct cardiac afferent mechanism, and this would not explain worsening ischemia specifically in microvascular disease.
Option D: Option D inverts the actual mechanism entirely: nitroglycerin does not preferentially dilate the microvasculature; it preferentially affects larger vessels (veins and epicardial arteries), and no reversal of the normal coronary pressure gradient occurs with nitrate administration.
20. A 63-year-old man with stable angina is started on metoprolol succinate. At his two-week follow-up, he reports that his anginal episodes have decreased from daily to two or three times per week. His resting heart rate is 74 bpm (down from 88 bpm pre-treatment) and his resting blood pressure is 144/88 mmHg. His physician notes that therapy has not yet reached its hemodynamic target. Which of the following correctly describes the hemodynamic targets for antianginal therapy based on the rate-pressure product framework?
A) The therapeutic target for antianginal therapy is complete elimination of all anginal symptoms; as long as the patient still reports any anginal episodes, hemodynamic targets have not been met regardless of heart rate or blood pressure
B) The therapeutic target is a resting heart rate below 50 bpm; heart rates in the 50–60 range are subtherapeutic and are associated with incomplete suppression of MVO2 at exercise intensities typical of daily activities
C) The therapeutic target is normalization of resting blood pressure to below 120/80 mmHg; heart rate is not a primary hemodynamic endpoint for antianginal therapy in the absence of specific tachycardia
D) The therapeutic targets are a resting heart rate of 55–60 beats per minute and a reduction in the resting rate-pressure product of at least 15–20% from the pre-treatment baseline; this patient's resting heart rate of 74 bpm indicates that the hemodynamic target has not yet been reached and the metoprolol dose should be uptitrated
E) The therapeutic target is a resting rate-pressure product below 10,000 mmHg·beats/min regardless of baseline; patients whose pre-treatment rate-pressure product was above this threshold require combination therapy to reach target
ANSWER: D
Rationale:
This question asked you to apply the rate-pressure product framework to assess whether antianginal therapy has achieved its hemodynamic target. Option D is correct: the established therapeutic targets in antianginal pharmacotherapy are a resting heart rate of 55–60 beats per minute and a reduction in the resting rate-pressure product of at least 15–20% from the pre-treatment baseline. In this patient, the resting heart rate has only decreased from 88 to 74 bpm — substantially above the target of 55–60 bpm. Despite symptomatic improvement (a good sign), the hemodynamic target has not been met, meaning that ordinary activities may still reach or approach the ischemic threshold even if the frequency of rest symptoms has improved. The appropriate response is uptitration of the metoprolol dose toward the heart rate target, provided hemodynamic tolerance allows. Symptom improvement without hemodynamic target attainment is incomplete therapy. Option A sets symptom elimination as the sole endpoint, which is clinically insufficient; the rate-pressure product framework defines specific hemodynamic targets that should be achieved independently of symptom reporting, because patients with ischemia may underreport or have variable symptom thresholds. Option B sets the target heart rate below 50 bpm, which is too aggressive: heart rates below 50 bpm are associated with symptomatic bradycardia, poor exercise tolerance, fatigue, and — in the presence of reactive airways disease or diabetes — an unacceptable side effect burden; the established target is 55–60 bpm, which balances anti-ischemic efficacy against tolerability. Option E proposes a fixed absolute rate-pressure product target of 10,000 mmHg·beats/min for all patients; antianginal therapy targets are defined as a percentage reduction from the individual patient's pre-treatment baseline, not as a uniform absolute number, because the ischemic threshold varies substantially between patients.
Option C: Option C incorrectly identifies blood pressure normalization as the primary hemodynamic endpoint and dismisses heart rate; while blood pressure management is relevant (it contributes to the rate-pressure product and to afterload), heart rate is the primary and most powerful anti-ischemic hemodynamic target in stable angina.
21. A 68-year-old woman with longstanding hypertension and left ventricular hypertrophy (LVH) on echocardiography presents with exertional chest pressure. Her coronary angiogram reveals no obstructive stenoses. Her cardiologist explains that LVH creates a specific vulnerability to subendocardial ischemia even in the absence of epicardial coronary disease. Which of the following best explains the physiological basis for this vulnerability?
A) Left ventricular hypertrophy reduces the total number of capillaries per unit of myocardial mass during the hypertrophic process, creating areas of absolute capillary rarefaction that are uniformly ischemic at rest regardless of demand
B) Left ventricular hypertrophy increases systolic wall stress by thickening the ventricular wall; per the Law of Laplace, greater wall thickness increases wall stress, raising MVO2 to levels that exceed coronary supply even at rest in severely hypertrophied ventricles
C) Left ventricular hypertrophy is associated with elevated left ventricular end-diastolic pressure and increased systolic compressive forces; subendocardial vessels, which operate at the lowest perfusion pressure and are most susceptible to compressive forces during systole, are disproportionately impaired — and the hypertrophied myocardium has increased MVO2 at baseline, further narrowing the supply-demand margin
D) Left ventricular hypertrophy causes epicardial coronary artery compression by the enlarged myocardial mass surrounding the vessel origins; the resulting extrinsic stenosis is not visible on standard angiography but produces functional obstruction equivalent to a 50–60% stenosis during exertion
E) Left ventricular hypertrophy produces intermittent coronary vasospasm by releasing endothelin-1 and other vasoconstrictors from hypertrophied cardiomyocytes; the vasospasm selectively affects subendocardial vessels because they are closest to the myocardial source of vasoconstrictor release
ANSWER: C
Rationale:
This question asked you to identify the physiological basis for subendocardial ischemia vulnerability in left ventricular hypertrophy. Option C is correct: the subendocardium is inherently the most vulnerable zone of the myocardium because it operates at the lowest perfusion pressure and is most exposed to compressive forces during systole. In a hypertrophied ventricle, these vulnerabilities are compounded: elevated left ventricular end-diastolic pressure (LVEDP) — common in LVH due to diastolic dysfunction — reduces the coronary perfusion pressure gradient (which equals aortic diastolic pressure minus LVEDP), specifically impairing subendocardial flow. Increased systolic compressive forces from the hypertrophied, pressure-overloaded ventricle further impair subendocardial perfusion during systole. Simultaneously, the greater myocardial mass of the hypertrophied ventricle consumes more oxygen at any given level of work. This combination — impaired subendocardial supply with increased total demand — produces a narrow supply-demand margin that can be crossed by modest increases in heart rate or wall stress, explaining angina and ischemia in the absence of any epicardial stenosis. Option A is partially true in concept (capillary rarefaction does occur with hypertrophy) but overstates the consequence: rarefaction does not produce uniform resting ischemia; it reduces the reserve available during stress and contributes to impaired coronary flow reserve, but most patients with LVH are not ischemic at rest. Option D is anatomically incorrect: LVH does not cause epicardial coronary compression; the epicardial arteries travel on the surface of the heart and are not compressed by myocardial mass regardless of ventricular wall thickness.
Option B: Option B inverts the Law of Laplace relationship: greater wall thickness reduces (not increases) wall stress per unit area — this is the short-term compensatory benefit of hypertrophy. The concern with LVH is the increased total MVO2 from greater myocardial mass, not increased wall stress per unit.
Option E: Option E conflates cardiac and vascular biology incorrectly: while hypertrophied cardiomyocytes do release autocrine and paracrine mediators including endothelin-1, this is not the established mechanism by which LVH produces subendocardial ischemia; it does not cause selective subendocardial vasospasm as a primary mechanism.
22. A 66-year-old man with CCS Class III angina remains symptomatic despite maximally tolerated doses of amlodipine 10 mg daily and isosorbide mononitrate 60 mg daily. His cardiologist explains that the difficulty reflects a fundamental limitation of single-drug and two-drug antianginal therapy. Which of the following best describes the pharmacological rationale for adding a third antianginal agent from a complementary class rather than increasing doses of existing medications?
A) Adding a third agent is preferred because dose escalation of existing agents invariably activates counter-regulatory neurohormonal systems, including the renin-angiotensin-aldosterone system, that neutralize the hemodynamic benefits achieved at lower doses — a phenomenon that does not occur when multiple low-dose agents are used
B) No single drug class addresses all four hemodynamic levers simultaneously, and each class has dose-limiting adverse effects that prevent indefinite escalation; combination therapy with agents from complementary classes achieves greater total MVO2 reduction at lower doses of each individual drug — improving efficacy while limiting adverse effects — because each additional agent pulls levers that the existing drugs do not reach
C) Adding a third agent is preferred because antianginal drugs exhibit pharmacodynamic synergy when combined — their combined effect is greater than the sum of their individual effects, a supraadditive response that cannot be achieved by increasing the dose of any single agent
D) Dose escalation of existing agents is limited by the risk of tachyphylaxis; all antianginal drugs develop complete tolerance within 72 hours of continuous use at any dose, making escalation pharmacologically futile beyond the initial dose-finding period
E) Adding a third agent from a different class improves outcomes primarily by addressing the psychological component of angina — patients with three medications feel more comprehensively treated and report fewer symptoms independent of any hemodynamic benefit, a placebo effect that accounts for most of the observed benefit of triple antianginal therapy
ANSWER: B
Rationale:
This question asked you to articulate the pharmacological rationale for combination therapy in angina and why adding a complementary agent is preferred over indefinite dose escalation of existing drugs. Option B is correct: no single drug class addresses all four pharmacological levers simultaneously. Amlodipine (a DHP-CCB) addresses afterload and coronary vasodilation. Isosorbide mononitrate addresses preload and provides additional coronary vasodilation. Heart rate and contractility — the most powerful anti-ischemic levers — are not addressed by either of these two agents. Adding a beta-blocker would engage the heart rate lever that both existing agents leave untouched, achieving greater total MVO2 reduction. Moreover, each drug class has dose-limiting adverse effects: further escalation of amlodipine causes peripheral edema; further escalation of nitrates is limited by headache, nitrate tolerance, and postural hypotension. By adding a third agent at a moderate dose rather than pushing two agents to their adverse-effect limits, the regimen improves efficacy at lower individual drug exposures. This principle of pharmacological complementarity is the explicit rationale for triple conventional antianginal therapy (beta-blocker + DHP-CCB + long-acting nitrate) in CCS Class III–IV patients. Option A invents a specific neurohormonal counter-regulatory mechanism (RAAS activation) as a dose-escalation limitation; while reflex neurohormonal activation does occur with some vasodilators, it is not a universal limitation that applies to all antianginal drugs, and RAAS activation is not the established reason why triple therapy is preferred over dose escalation of existing agents. Option E dismisses the hemodynamic basis of combination therapy as primarily a placebo effect, which is incorrect; the rationale for triple antianginal therapy is firmly grounded in pharmacological complementarity, with clinical benefit driven by measurable reductions in heart rate, blood pressure, and rate-pressure product.
Option C: Option C describes pharmacodynamic synergy (supraadditivity), which is a pharmacological term meaning the combined effect exceeds the sum of individual effects; standard antianginal combination therapy is additive, not synergistic in this strict sense — the rationale is complementarity and adverse effect limitation, not supraadditivity.
Option D: Option D incorrectly states that all antianginal drugs develop complete tachyphylaxis within 72 hours; nitrate tolerance does develop with continuous use (particularly with short-acting preparations and without a nitrate-free interval), but beta-blockers and calcium channel blockers do not develop tachyphylaxis, and dose escalation of these agents beyond their first dose is pharmacologically valid.
BEFORE YOU MOVE ON
You have just worked through the conceptual architecture of myocardial ischemia and antianginal pharmacology — the supply-demand framework, the ischemic cascade, the three major angina subtypes, the four hemodynamic levers, and the key contraindications that arise when the wrong drug is applied to the wrong angina mechanism. This is not background material. Every drug you will encounter in the modules ahead — nitrates, beta-blockers, calcium channel blockers, ranolazine, ivabradine — derives its clinical identity entirely from which of these levers it pulls and in which direction. A drug that works beautifully in stable exertional angina may be contraindicated or frankly dangerous in vasospastic angina; a combination that is synergistically effective may become life-threatening with one additional medication error. The framework you built here is the scaffold on which everything that follows will hang.
You are now at the entrance to Chapter 9, which covers the full antianginal pharmacological toolkit across seven modules. Module 1 — the one you just completed — is the only module in this chapter that contains no drug names. Every subsequent module will introduce specific drug classes in depth: nitrates in Module 2, beta-blockers and calcium channel blockers in Modules 3 and 4, and newer agents in Modules 5 through 7. When you reach those modules, come back to the question you got wrong here — the one about the ischemic cascade sequence, or the one about vasospastic angina and beta-blockers — and you will find it easier the second time.
If you are moving directly to Tier 1, you will find that Tier 1 deepens the same concepts with more precise mechanistic discrimination and begins introducing the specific drugs. The conceptual vocabulary you have now — supply-demand balance, rate-pressure product, the four levers, the angina subtypes and their distinct mechanisms — is exactly what Tier 1 assumes you have. You are ready.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.